U.S. Hydronephrosis Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Hydronephrosis Market
- ✓Market Size 2024: USD 1.82 billion
- ✓Market Size 2032: USD 2.61 billion
- ✓CAGR: 4.6%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Ambulatory Distribution Now: Medical device suppliers should secure ambulatory surgical center contracts and GPO listings with Vizient and Premier before the first quarter of 2026. Outpatient urology volume is consolidating under group purchasing agreements, and late entrants will face closed formularies through 2032.
U.S. Hydronephrosis: Market Overview
The U.S. hydronephrosis market is distinct because it is not a standalone product category but a clinical outcome addressed through diagnostic imaging, urological devices, and reconstructive surgery. Domestic spending reached USD 1.82 billion in 2024, representing roughly 38% of global spending on obstruction-related urology care. Unlike global demand, which is driven by infection and stone management in low-income settings, U.S. demand reflects prenatal screening pathways, high pediatric detection rates, and a growing elderly population with benign prostatic hyperplasia.
Structurally, the market is split between capital-intensive imaging and disposable urological consumables. Ultrasound and CT urography generate the largest revenue pool, while ureteral stents, nephrostomy tubes, and ureteroscopy sheaths from Boston Scientific, Cook Medical, and Teleflex account for recurring supply revenue. The market is more concentrated in hospital purchasing than most global markets, because Medicare reimbursement under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment rules sets pricing for nearly every procedure.
Growth Drivers in U.S. Hydronephrosis Care
Prenatal detection is the first driver. The American Academy of Pediatrics follows antenatal hydronephrosis grading guidance, and roughly 3.6 million U.S. live births each year feed postnatal urological follow-up. Medicaid expansion in 40 states has widened access to these pathways, and pediatric referrals for moderate to severe cases drive repeat ultrasound and voiding cystourethrography volumes across children's hospitals. Renal ultrasound codes CPT 76770 and 76775 remain reimbursed at stable rates, supporting high utilization.
An aging population adds a second driver. Benign prostatic hyperplasia affects most men over 60, and bladder outlet obstruction frequently produces secondary hydronephrosis that requires stenting or nephrostomy. The Census Bureau projects 73 million Americans aged 65 and older by 2030, expanding the pool for these interventions. The third driver is robotic reconstruction, as Intuitive Surgical's da Vinci systems, installed across thousands of U.S. hospitals, increasingly support pyeloplasty for ureteropelvic junction obstruction in adults and children.
Market Restraints and Entry Barriers
Entry is constrained first by FDA premarket requirements. Ureteral stents, nephrostomy catheters, and ureteroscopes are generally Class II devices under 21 CFR Part 876, cleared through 510(k) notifications against an existing predicate. The Quality Management System Regulation, which incorporates ISO 13485 from February 2, 2026, adds audit burden for suppliers without established U.S. manufacturing controls. Imaging software that grades hydronephrosis severity without a predicate follows the longer De Novo route, adding months to launch timelines.
Pricing and incumbency present the second barrier. Medicare's Ambulatory Surgical Center payment system and group purchasing organizations such as Vizient and Premier lock multi-year contracts, leaving new entrants competing against Cook Medical and Boston Scientific on established formularies. Distribution complexity adds cost, because stents require sterile packaging, hospital value analysis committee approval, and rapid reorder support across roughly 6,000 acute-care hospitals.
Market Opportunities in the United States
Ambulatory urology is the nearest opportunity. Medicare has progressively expanded the ASC covered procedures list to include urological endoscopy, and an estimated USD 410 million of ureteral stent and ureteroscopy consumable spend still sits in hospital outpatient departments. That volume is positioned to migrate to ASCs by 2030, giving suppliers with outpatient-sized packaging and bundled pricing a window before contracts consolidate. Urology ASCs in Texas, Florida, and Georgia show the fastest case growth, making regional distribution agreements the first priority.
Point-of-care ultrasound in urgent care and primary care is the second opportunity. Handheld ultrasound units priced below USD 10,000 are entering urgent care chains, and an estimated USD 260 million of renal screening demand in these settings remains underserved by specialist imaging. Urgent care chains operating over 1,000 U.S. clinics provide the distribution backbone. AI-assisted grading software cleared through the FDA De Novo pathway can capture this segment before 2028, because few competitors have completed clearance.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 1.82 billion |
| Market Size 2032 | USD 2.61 billion |
| Growth Rate (CAGR) | 4.6% |
| Most Critical Decision Factor | Alignment with ASC and outpatient payment rules |
| Largest Region | South Region |
| Competitive Structure | Moderately consolidated, with the top five suppliers holding majority share |
Leading Market Participants
- Boston Scientific
- Cook Medical
- Teleflex
- Coloplast
- Becton Dickinson
- Olympus Corporation
- Karl Storz
- Intuitive Surgical
- GE HealthCare
- Philips
Regulatory and Policy Environment
Device commercialization is governed by the Federal Food, Drug, and Cosmetic Act, with ureteral stents and nephrostomy catheters cleared by the FDA's Center for Devices and Radiological Health through 510(k) notifications, targeting a 90 FDA-day review goal under the Medical Device User Fee Amendments. The Quality Management System Regulation takes full effect on February 2, 2026, requiring manufacturers to align quality systems with ISO 13485:2016. Hydronephrosis grading software without a predicate device requires De Novo classification, a process that typically extends launch timelines by several months.
Reimbursement rules are set by the Centers for Medicare and Medicaid Services. The CY2025 Medicare Physician Fee Schedule and Outpatient Prospective Payment System final rules determine procedure payment, while the Ambulatory Surgical Center covered procedures list governs site-of-service decisions for urological surgery. Medicaid expansion, backed by a 90% federal match under the Affordable Care Act, supports pediatric access. Manufacturers must comply with the Anti-Kickback Statute and Open Payments reporting under the Sunshine Act, with annual disclosure filed each spring.
Long-Term Outlook for Hydronephrosis in the U.S.
By 2032, the U.S. hydronephrosis market is projected to reach USD 2.61 billion, with outpatient settings capturing a rising share of stent, nephrostomy, and ureteroscopy procedures. Ultrasound will remain the primary diagnostic entry point for suspected obstruction, while CT urography retains share in adult trauma and oncologic staging. Robotic reconstruction will grow steadily rather than rapidly, because pediatric and adult pyeloplasty volumes remain constrained by surgeon training capacity and case scheduling at academic centers.
Competitive dynamics will hinge on outpatient-ready packaging, AI-assisted severity grading, and value-based contracts with integrated delivery networks. Boston Scientific and Cook Medical will defend stent share through formulary breadth, while point-of-care ultrasound suppliers gain ground in primary care and urgent care. Prenatal screening guidance and Medicaid coverage will provide the clearest demand floor through 2032, regardless of cyclical hospital capital budgets.
Frequently Asked Questions
Market Segmentation
- Hospitals
- Ambulatory Surgical Centers
- Urology Clinics
- Ambulatory Imaging Centers
- Children's Hospitals
- Prenatal and Neonatal
- Pediatric
- Adult
- Geriatric
- Ultrasonography
- CT Urography
- MR Urography
- Nuclear Renography
- Voiding Cystourethrography
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.